Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
NEW YORK, Nov. 30, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of New Jersey on behalf of investors who purchased Amicus Therapeutics, Inc. (NASDAQ:FOLD) securities between March 19, 2015 and October 1, 2015.
Click here to learn about the case: http://docs.wongesq.com/FOLD-Info-Request-Form-939. There is no cost or obligation to you.
The complaint alleges that the Company made false and/or misleading statements and/or failed to disclose that the United States Food and Drug Administration raised concerns about Amicus Therapeutics’ forthcoming new drug application for migalastat during their September 15, 2015 meeting.
On October 2, 2015, Amicus Therapeutics revealed it would no longer be in a position to submit its NDA in the fourth quarter of 2015. Upon this news, shares of Amicus Therapeutics fell 54% to close at $6.39 per share.
If you suffered a loss in Amicus Therapeutics you have until December 7, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/FOLD-Info-Request-Form-939.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
